I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Bellicum Pharmaceuticals (BLCM) proposes 5M share offering at $12.00 per share

March 22, 2017

  BLCM closed DOWN -$1.47 at $12.90 Thursday, having been UP +$0.46 to $14.37 and is DOWN -$0.16 or -1.24% in the aftermarket    

REGENXBIO (RGNX) proposes 3.7 M share offering priced at $20.50 for proceeds of $75 M

March 21, 2017

  RGNX drops $2.00 or -8.23% to $22.10, the pre-market is down -$1.35 or -6.11% 3.7 M shares are priced at $20.50  

Northwest Bio (NWBO) yet another offering, this time of $7.5 M

March 17, 2017

  Priced at $0.26 …   Most of the proceeds are spoken for to many past investors having negotiated a $11 M note payment schedule with Whitebox Advisors and total liabilities of $53.9 M as of Sept. 30 including a $135,000 6% senior unsecured note that matured in 2011, an 8% unsecured note for $50 K held by a related party, and a mortgage for 10.3 M at 12%. NWBO is DOWN -$0.098 or -28.43% to $0.25  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.